Tech Company Financing Transactions
EdiGene Funding Round
EdiGene closed a Series B investment round on 8/9/2018. Backers included Lilly Asia Ventures, Huagai Capital and IDG Capital Partners.
Transaction Overview
Company Name
Announced On
8/9/2018
Transaction Type
Venture Equity
Amount
Unknown
Round
Series B
Investors
Proceeds Purpose
This investment will allow us to continue advancing our promising portfolio of therapeutic programs based on gene-editing technologies, said Dr. Dong Wei, CEO of EdiGene.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
245 1st St. Riverview II 18th Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
EdiGene is a world leading genome editing company founded in 2015. The mission of EdiGene is to translate the cutting-edge genome editing technologies into novel therapeutics for genetic diseases and cancer, and into creative solutions to advance drug discovery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dong Wei
Chief Operating Officer
David Si
Chief Technical Officer
Pengfei Yuan
Founder
Wensheng Wei
VP - R & D
Riguo Fang
Browse more venture capital transactions:
Prev: 8/8/2018: Akouos venture capital transaction
Next: 8/9/2018: Capsule8 venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs